NDT Advance Access originally published online on April 26, 2005
Nephrology Dialysis Transplantation 2005 20(7):1443-1449; doi:10.1093/ndt/gfh820
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Hypersensitivity reactions and deaths associated with intravenous iron preparations
1 Albany Nephrology Pharmacy (ANephRx) Group, Albany, NY, 2 Nephrology Pharmacy Associates, Inc., Ann Arbor, MI, 3 Renal Research Institute, LLC, New York, NY, 4 Galt Associates, Blue Bell, PA and 5 Luitpold Pharmaceuticals, Inc., Norristown, PA, USA
Correspondence and offprint requests to: George R. Bailie, PharmD, PhD, Albany College of Pharmacy, 106 New Scotland Avenue, Albany, NY 12208, USA. Email: bailieg{at}acp.edu
Background. Parenteral iron therapy is an accepted adjunctive management of anaemia in kidney disease. Newer agents may have fewer severe hypersensitivity adverse events (AE) compared with iron dextrans (ID). The rate of type 1 AE to iron sucrose (IS) and sodium ferric gluconate (SFG) relative to ID is unclear. We used the US Food and Drug Administration's Freedom of Information (FOI) surveillance database to compare the type 1 AE profiles for the three intravenous iron preparations available in the United States.
Methods. We tabulated reports received by the FOI database between January 1997 and September 2002, and calculated 100 mg dose equivalents for the treated population for each agent. We developed four clinical categories describing hypersensitivity AE (anaphylaxis, anaphylactoid reaction, urticaria and angioedema) and an algorithm describing anaphylaxis, for specific analyses.
Results. All-event reporting rates were 29.2, 10.5 and 4.2 reports/million 100 mg dose equivalents, while all-fatal-event reporting rates were 1.4, 0.6 and 0.0 reports/million 100 mg dose equivalents for ID, SFG and IS, respectively. ID had the highest reporting rates in all four clinical categories and the anaphylaxis algorithm. SFG had intermediate reporting rates for urticaria, anaphylactoid reaction and the anaphylaxis algorithm, and a zero reporting rate for the anaphylaxis clinical category. IS had either the lowest or a zero reporting rate in all clinical categories/algorithm.
Conclusions. These findings confirm a higher risk for AE, especially serious type 1 reactions, with ID therapy than with newer intravenous iron products and also suggest that IS carries the lowest risk for hypersensitivity reactions.
Keywords: hypersensitivity reactions; intravenous iron; iron dextran; iron sucrose; sodium ferric gluconate; type 1 reactions
The authors wish it to be known that P.L. Lane died before this manuscript was completed.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. B. Silverstein, J. A. Gilreath, and G. M. Rodgers Intravenous Iron Therapy: A Summary of Treatment Options and Review of Guidelines Journal of Pharmacy Practice, December 1, 2008; 21(6): 431 - 443. [Abstract] [PDF]
|
|
|
|
 |
|
 A. Hayat Safety Issues With Intravenous Iron Products in the Management of Anemia in Chronic Kidney Disease Clin. Med. Res., December 1, 2008; 6(3-4): 93 - 102. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. S. Spinowitz, A. T. Kausz, J. Baptista, S. D. Noble, R. Sothinathan, M. V. Bernardo, L. Brenner, and B. J. G. Pereira Ferumoxytol for Treating Iron Deficiency Anemia in CKD J. Am. Soc. Nephrol., August 1, 2008; 19(8): 1599 - 1605. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Tomasello Anemia of Chronic Kidney Disease Journal of Pharmacy Practice, June 1, 2008; 21(3): 181 - 195. [Abstract] [PDF]
|
|
|
|
 |
|
 L. Schaefer and R. M. Schaefer A primer on iron therapy Nephrol. Dial. Transplant., September 1, 2007; 22(9): 2429 - 2431. [Full Text] [PDF]
|
|
|
|
|
|
A. F. de Vecchi, C. Novembrino, S. Lonati, S. Ippolito, and F. Bamonti Two different modalities of iron gluconate i.v. administration: effects on iron, oxidative and inflammatory status in peritoneal dialysis patients Nephrol. Dial. Transplant., June 1, 2007; 22(6): 1709 - 1713. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. H. Buus and J. D. Jensen Severe intravascular haemolysis and acute renal failure following intravenous administration of iron dextran Nephrol. Dial. Transplant., February 1, 2007; 22(2): 661 - 662. [Full Text] [PDF]
|
|
|
|
|
|
W. H. Horl Clinical Aspects of Iron Use in the Anemia of Kidney Disease J. Am. Soc. Nephrol., February 1, 2007; 18(2): 382 - 393. [Full Text] [PDF]
|
|
|
|
 |
|
 H. Singh, J. Reed, S. Noble, J. L. Cangiano, D. B. Van Wyck, and for the United States Iron Sucrose (Venofer) Clini Effect of Intravenous Iron Sucrose in Peritoneal Dialysis Patients Who Receive Erythropoiesis-Stimulating Agents for Anemia: A Randomized, Controlled Trial Clin. J. Am. Soc. Nephrol., May 1, 2006; 1(3): 475 - 482. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. M. Chertow, P. D. Mason, O. Vaage-Nilsen, and J. Ahlmen Update on adverse drug events associated with parenteral iron Nephrol. Dial. Transplant., February 1, 2006; 21(2): 378 - 382. [Abstract] [Full Text] [PDF]
|
|